MX2018011288A - Forma fisica de un modulador sgr. - Google Patents
Forma fisica de un modulador sgr.Info
- Publication number
- MX2018011288A MX2018011288A MX2018011288A MX2018011288A MX2018011288A MX 2018011288 A MX2018011288 A MX 2018011288A MX 2018011288 A MX2018011288 A MX 2018011288A MX 2018011288 A MX2018011288 A MX 2018011288A MX 2018011288 A MX2018011288 A MX 2018011288A
- Authority
- MX
- Mexico
- Prior art keywords
- sgr
- modulator
- physical form
- phenylb
- utan
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Amplifiers (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Abstract
Una forma cristalina de 2,2-difluoro-N-[(1R,2S)-3-metil-1-{[1-(1-m etil-6-oxo-1,6-dihidropiridin-3-il)-1H-indazol-5-iI]oxi}-1-fenilb utan-2-il]propanamida (forma C), composiciones farmacéuticas que la contienen y su uso en terapia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2016/077095 WO2017161518A1 (en) | 2016-03-23 | 2016-03-23 | New physical form |
| PCT/EP2017/056838 WO2017162747A1 (en) | 2016-03-23 | 2017-03-22 | Physical form of a sgr modulator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018011288A true MX2018011288A (es) | 2019-06-13 |
| MX387467B MX387467B (es) | 2025-03-18 |
Family
ID=58398193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018011288A MX387467B (es) | 2016-03-23 | 2017-03-22 | Forma física de un modulador sgr. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10407404B2 (es) |
| EP (1) | EP3433248B1 (es) |
| JP (1) | JP6651648B2 (es) |
| KR (1) | KR102168931B1 (es) |
| CN (1) | CN109415348B (es) |
| AU (1) | AU2017238341A1 (es) |
| CA (1) | CA3016507C (es) |
| CL (1) | CL2018002577A1 (es) |
| ES (1) | ES2926059T3 (es) |
| IL (1) | IL261367A (es) |
| MX (1) | MX387467B (es) |
| SG (1) | SG11201807228QA (es) |
| WO (2) | WO2017161518A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4086247A4 (en) * | 2019-12-31 | 2023-12-06 | Medshine Discovery Inc. | BENZOPYRAZOLE COMPOUND |
| US20240246985A1 (en) * | 2021-06-28 | 2024-07-25 | Medshine Discovery Inc. | Crystal form of triazolopyridine-substituted indazole compound and preparation method therefor |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008543780A (ja) * | 2005-06-10 | 2008-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルココルチコイド模倣薬、それらの製造方法、医薬組成物及びそれらの使用 |
| TW200815361A (en) | 2005-10-20 | 2008-04-01 | Astrazeneca Ab | Chemical compounds |
| WO2007114763A1 (en) | 2006-03-31 | 2007-10-11 | Astrazeneca Ab | Sulphonamide derivates as modulators of the glucocorticoid receptor |
| EP1878717A1 (en) | 2006-07-14 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Benzyl amines, a process for their production and their use as anti-inflammatory agents |
| EP1917963A1 (en) | 2006-10-31 | 2008-05-07 | Bayer Schering Pharma Aktiengesellschaft | Cyclic phenyl-substituted indazols, a process for their production and their use as anti-inflammatory agents |
| EP1921067A1 (en) | 2006-11-08 | 2008-05-14 | Bayer Schering Pharma Aktiengesellschaft | Indole and indazole derivatives as anti-inflammatory agents |
| WO2008055709A1 (en) | 2006-11-08 | 2008-05-15 | Bayer Schering Pharma Aktiengesellschaft | Indazole and indole derivatives as anti -inflammatory agents |
| TW200829578A (en) * | 2006-11-23 | 2008-07-16 | Astrazeneca Ab | Chemical compounds 537 |
| JO2754B1 (en) * | 2006-12-21 | 2014-03-15 | استرازينكا ايه بي | Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders |
| WO2008079073A1 (en) | 2006-12-22 | 2008-07-03 | Astrazeneca Ab | Indazolyl sulphonamide derivatives for the treatment of glucocorticoid receptor mediated disorders |
| EP1958934A1 (en) | 2007-02-16 | 2008-08-20 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydronaphthalenylamides, a process for their production and their use as anti-inflammatory agents |
| EP2062880A1 (en) | 2007-11-22 | 2009-05-27 | Bayer Schering Pharma Aktiengesellschaft | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents |
| EP2072509A1 (en) | 2007-12-18 | 2009-06-24 | Bayer Schering Pharma Aktiengesellschaft | 1-Aryl-1H-quinoline-2-ones: process for their production and their use as anti-inflammatory agents |
| TWI445705B (zh) * | 2008-05-20 | 2014-07-21 | Astrazeneca Ab | 經苯基及苯并二基取代之吲唑衍生物 |
| EP2149558A1 (en) | 2008-07-21 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino-1-arylquinolin-2-ones, a process for their production and their use as anti-inflammatory agents |
| US8268820B2 (en) * | 2009-03-26 | 2012-09-18 | Hoffmann-La Roche Inc. | 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds |
| CA2839398A1 (en) | 2011-06-29 | 2013-01-03 | Bayer Intellectual Property Gmbh | Crystalline form of indazolyl amide derivatives for the treatment glucocorticoid receptor mediated disorders |
| JP6430000B2 (ja) * | 2014-09-26 | 2018-11-28 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | １−アルキル−６−オキソ−１，６−ジヒドロピリジン−３−イル化合物及びｓｇｒｍモジュレーターとしての使用 |
-
2016
- 2016-03-23 WO PCT/CN2016/077095 patent/WO2017161518A1/en not_active Ceased
-
2017
- 2017-03-22 CA CA3016507A patent/CA3016507C/en active Active
- 2017-03-22 MX MX2018011288A patent/MX387467B/es unknown
- 2017-03-22 SG SG11201807228QA patent/SG11201807228QA/en unknown
- 2017-03-22 WO PCT/EP2017/056838 patent/WO2017162747A1/en not_active Ceased
- 2017-03-22 EP EP17712779.2A patent/EP3433248B1/en active Active
- 2017-03-22 JP JP2018548920A patent/JP6651648B2/ja active Active
- 2017-03-22 AU AU2017238341A patent/AU2017238341A1/en not_active Abandoned
- 2017-03-22 KR KR1020187028158A patent/KR102168931B1/ko not_active Expired - Fee Related
- 2017-03-22 CN CN201780019695.XA patent/CN109415348B/zh active Active
- 2017-03-22 US US16/085,717 patent/US10407404B2/en active Active
- 2017-03-22 ES ES17712779T patent/ES2926059T3/es active Active
-
2018
- 2018-08-26 IL IL261367A patent/IL261367A/en unknown
- 2018-09-10 CL CL2018002577A patent/CL2018002577A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX387467B (es) | 2025-03-18 |
| CN109415348A (zh) | 2019-03-01 |
| US20190106402A1 (en) | 2019-04-11 |
| CN109415348B (zh) | 2021-09-03 |
| ES2926059T3 (es) | 2022-10-21 |
| WO2017161518A1 (en) | 2017-09-28 |
| KR20180117178A (ko) | 2018-10-26 |
| US10407404B2 (en) | 2019-09-10 |
| WO2017162747A1 (en) | 2017-09-28 |
| SG11201807228QA (en) | 2018-10-30 |
| CA3016507C (en) | 2020-10-13 |
| EP3433248B1 (en) | 2022-06-22 |
| CL2018002577A1 (es) | 2018-12-21 |
| CA3016507A1 (en) | 2017-09-28 |
| JP2019508474A (ja) | 2019-03-28 |
| IL261367A (en) | 2018-10-31 |
| KR102168931B1 (ko) | 2020-10-23 |
| EP3433248A1 (en) | 2019-01-30 |
| JP6651648B2 (ja) | 2020-02-19 |
| AU2017238341A1 (en) | 2018-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020000145A2 (es) | Carboxamidas como moduladores de los canales de sodio | |
| AR121273A2 (es) | Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende | |
| PH12019500637A1 (en) | Calpain modulators and therapeutic uses thereof | |
| MX2020005063A (es) | Inhibidores de kras g12c. | |
| CL2017000240A1 (es) | Compuestos activos hacia bromodominios | |
| WO2018075692A3 (en) | Antibody constructs | |
| BR112015023417A2 (pt) | compostos heterocíclicos e seus usos | |
| CL2013003313A1 (es) | Compuestos derivados de 2,4-diaminoquinazolinas, sales o solvatos farmacéuticamente aceptables; composición farmacéutica que los comprende; y uso en el tratamiento de un trastorno en el que interviene la modulación de tlr7 y/o tlr8. | |
| PE20150646A1 (es) | Metodos de tratamiento de una tauopatia | |
| SG10201808151RA (en) | Cortistatin analogues and syntheses and uses thereof | |
| MX2015016627A (es) | Vacuna para la malaria. | |
| MX2017002239A (es) | Composicion que contiene cineol para la administracion nasal. | |
| HUE061963T2 (hu) | Karbamid-vegyületek és készítmények mint SMARCA2/BRM-ATPáz gátlók | |
| IL283539A (en) | 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same | |
| UY36761A (es) | Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma | |
| UY37342A (es) | Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos | |
| MX2017000676A (es) | Oritavancina de alta pureza y metodo para producir la misma. | |
| EP3626283A4 (en) | SEALED DRUG DISTRIBUTION AND ADMINISTRATION SYSTEM | |
| PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
| CY1121105T1 (el) | Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv | |
| CY1123408T1 (el) | Φαρμακευτικες συνθεσεις και χρηση των αυτων | |
| CY1125399T1 (el) | Διαρυλικες συνθεσεις και μεθοδοι για τη διαμορφωση ενος καταρρακτη κινασης | |
| CY1118277T1 (el) | Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης | |
| MX2018011288A (es) | Forma fisica de un modulador sgr. | |
| DOP2019000015A (es) | Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos |